

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently Amended) [The]An antibody-toxic moiety conjugate [of claim 1, wherein the antibody is]comprising (a) an antibody that is specifically reactive with CTLA4 and (b) a toxic moiety.
3. (Currently Amended) The antibody- toxic moiety conjugate of claim 2, wherein the antibody is [specially] specifically reactive with human CTLA4.
4. (Original) The antibody- toxic moiety conjugate of claim 2, wherein the antibody is a monoclonal antibody.
5. (Original) The antibody- toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 molecule that blocks the binding of CTLA4 to CD80 or CD86.
6. (Original) The antibody- toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 in spatial proximity to the site of CTLA4 binding to a costimulatory molecule.
7. (Currently Amended) The antibody-toxic moiety conjugate of claim 2, wherein the substitution of amino acid 83 in the amino acid sequence of human CTLA4 shown in SEQ ID NO: 2 results in reduced binding of the antibody by at least about 80% compared to a human CTLA4 [an antibody] without the substitution of amino acid 83.

8. (Original) The antibody- toxic moiety conjugate of claim 2, wherein the toxic moiety is a carbohydrate.

9. (Original) The antibody- toxic moiety conjugate of claim 8, wherein the carbohydrate is calicheamicin.

10. (Original) The antibody- toxic moiety conjugate of claim 2, wherein the toxic moiety is a naturally occurring bacterial product.

11. (Original) The antibody- toxic moiety conjugate of claim 10, wherein the toxic moiety is selected from the group consisting of ricin A chain and saporin.

12. (Canceled)

13. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the antibody is humanized.

14. (Original) A humanized antibody that is specifically reactive with human CTLA4, wherein the antibody comprises the amino acid sequence shown in SEQ ID NO: 8.

15. (Original) A humanized antibody that is specifically reactive with human CTLA4, wherein the antibody comprises the amino acid sequence shown in SEQ ID NO: 10.

16. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody-toxic moiety conjugate of claim 2.

17. (Withdrawn) The method of claim 16, wherein the antibody-toxic moiety conjugate is administered to a subject and the step of contacting is performed *in vivo*.

18. (Withdrawn) The method of claim 17, wherein the subject is suffering from a disorder or condition that would benefit from downmodulation of an ongoing

immune response wherein the disorder or condition is selected from the group consisting of: an autoimmune disorder, an immune response to a graft, an allergic response, an immune response to a therapeutic protein.

19. (Withdrawn) The method of claim 16, wherein the step of contacting is performed *in vitro*.

20. (Withdrawn) A method of modulating the immune response comprising contacting a cell within an antibody specifically reactive with CTLA4, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____), ATCC Accession No. ____ (hybridoma ____).

21. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:8.

22. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:10.

23. (Withdrawn) A method of downmodulating the immune response comprising contacting a cell with an antibody-toxic moiety conjugate, wherein the antibody specifically recognizes CTLA4.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com